BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

BioMarin Pharmaceutical currently trades at $61.02 per share and has shown little upside over the past six months, posting a middling return of 3.5%. Does th...

Topics Regulatory Compliance

2 Reasons to Like BMRN (and 1 Not So Much)

March 02, 2026

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss ↗

February 23, 2026

Via Chartmill

January 24, 2026

Via Chartmill

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate ↗

January 02, 2026

Via Chartmill

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗

December 19, 2025

Via Stocktwits

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

Topics Regulatory Compliance

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 17% year on year to $874.6 million. The company expects the...

Topics Regulatory Compliance

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

February 23, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday after market close. Here’s what to look for.

Topics Earnings

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

February 21, 2026

There's no need to hurry in buying this biotech stock.

Topics Artificial Intelligence Government World Trade

Should You Buy BioMarin Pharmaceutical Before Feb. 18? ↗

January 31, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Topics Earnings

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

January 08, 2026

The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two...

Topics Artificial Intelligence

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

A new year brings new opportunities to grow your wealth on Wall Street.

Topics Artificial Intelligence Economy Energy

10 Magnificent Stocks That Can Make You Richer in 2026 ↗

January 05, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Topics Economy Stocks World Trade

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Economy Intellectual Property

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq

Topics ETFs Intellectual Property

December 23, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

December 23, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the afternoon session after the stock's positive momentum continued as the company agreed to acquire Amicus Therapeutics...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 19% in the afternoon session after the company announced it agreed to acquire Amicus Therapeutics for approximately $4.8 billion...

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

December 19, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Topics Economy

Which stocks are gapping on Friday? ↗

December 19, 2025

Via Chartmill

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

December 15, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

December 08, 2025

BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth...

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

Topics Regulatory Compliance

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

Topics Regulatory Compliance

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

Topics Regulatory Compliance

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

BioMarin Pharmaceutical currently trades at $55.56 per share and has shown little upside over the past six months, posting a small loss of 4.4%. The stock also fell short of the S&P 500’s 11.5% gain...

2 Reasons to Like BMRN and 1 to Stay Skeptical

November 24, 2025

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

Topics Stocks

November 23, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin...

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

Topics Artificial Intelligence

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...